Riley Wealth Management chief market strategist Art Hogan discusses whether the Fed's interest rate move changed his investment focus on 'The Claman Countdown.' Euro Pacific Capital chief economist ...

FDA Commissioner Robert Califf is closing the book on his second stint leading the agency that regulates products accounting ...

The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.

Artbio, a clinical-stage radiopharmaceutical company, named Johnson & Johnson alum Margaret Yu as chief medical officer. Saisei Ventures tapped Dr. Sven Kili as partner. OSE Immunotherapeutics ...

The biopharmaceutical industry is aiming for a 2025 reversal of last year's slump in investor returns but remains wary over ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

We recently published an article titled Jim Cramer Discussed These 21 Stocks As Bond Yields Soared. In this article, we are ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine ...

At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.